INDOLENT SYSTEMIC MASTOCYTOSIS
Clinical trials for INDOLENT SYSTEMIC MASTOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new INDOLENT SYSTEMIC MASTOCYTOSIS trials appear
Sign up with your email to follow new studies for INDOLENT SYSTEMIC MASTOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for managing rare mast cell disease
Disease control Recruiting nowThis study follows 80 adults in Germany with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. Researchers will track how well avapritinib works in real-world settings over up to 24 months, focusing on quality of life and symptom control…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
New drug offers hope for mastocytosis patients
Disease control Recruiting nowThis study tests a new drug called elenestinib (BLU-263) for people with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. About 534 adults will receive either the study drug or a placebo, plus standard symptom therapy. The goal is to se…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Phase: PHASE2, PHASE3 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New study tracks daily life with rare mast cell disorder
Knowledge-focused Recruiting nowThis study watches how indolent systemic mastocytosis (ISM) affects people in everyday life. Researchers will collect information on symptoms, treatments, and quality of life from 150 adults. No new drugs are tested; the goal is to learn more about the disease and how it is manag…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC